Скачать с ютуб TCT 2022: 1Y Outcomes of Portico™ Valve in Pts with Severe Aortic Stenosis | Prof Helge Möllmann в хорошем качестве

TCT 2022: 1Y Outcomes of Portico™ Valve in Pts with Severe Aortic Stenosis | Prof Helge Möllmann

Watch on Radcliffe Cardiology: https://www.icrjournal.com/video-inde... Prof Helge Möllmann joins us to discuss the findings of a study that aimed to evaluate the procedural safety and device performance of Abbott's Portico™ TAVI Valve in patients with severe symptomatic degenerative aortic stenosis. Originally presented at TCT 22, The CONFIDENCE Registry involved over 1000 patients with NYHA Class ≥ II Aortic Stenosis who received transcatheter aortic heart valve implantation with the Portico™ Valve in experienced TAVI Centers across the world. Questions: 1. What is the importance of this study? 2. Please describe the difference between the Portico and FlexNav Delivery systems. 3. What was the study design and main outcomes? 4. How should these findings impact practice? 5. Where are the knowledge gaps, and how can these be overcome with further research? Recorded remotely from Dortmund, 2022. This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.